Different roles of SALL4 and OCT3/4 in the development and evolving processes of benign and malignant germ cells.

e17006 Background: In gonadogenesis, OCT3/4 and SALL4 are expressed in early germ cells and are critical for maintaining their pluripotency by suppressing differentiation. It is important to understand the variable expression of these two biomarkers throughout different stages of embryonic development as well as in tumor development. The primary aim of this study was to analyze SALL4 and OCT3/4 nuclear expression in various stages of fetal testes and examine their potential link to the risk of cryptorchidism in relation to later testicular tumor development. The second aim was to investigate the different expression patterns of SALL4 and OCT3/4 in metastatic germ cell tumors (GCT). Methods: Surgical and autopsy fetal testes ranging from 10 weeks of gestation to 11 months (n=10) were immunochemically stained for SALL4 and OCT3/4. OCT3/4 and SALL4 immunostains were further tested in 12 specimens from 11 patients with metastatic GCT. Results: SALL4 expression was maintained from early gonadogenesis within germ cells and persists regardless of age or malignant transformation. Whereas OCT3/4 expression started to diminish midway through the 3 rd trimester. Expression of OCT3/4 was retained in a case of a cryptorchid testicle, suggesting that continued expression of OCT3/4 may be linked to an increased risk of GCT in individuals with cryptorchid testicles. OCT3/4 expression returned in germ cell neoplasia in situ and undifferentiated GCTs such as seminoma and embryonal carcinoma. Only 2/12 (17%) metastatic GCT were positive for both SALL4 and OCT3/4, but the majority of metastatic GCT (83% 10/12 cases) continued to evolve by losing expressions of OCT3/4 and maintaining expression of SALL4 (Table 1). Conclusions: Our data demonstrates bridging associations from OCT3/4 and SALL4 expressions in embryonal testis development to their presence in metastatic GCT, indicating a continuous evolving process from benign germ cells to malignant GCT. SALL4 is an important marker for identifying GCT in metastatic sites, whereas metastatic GCTs often lose OCT3/4 expression during progression. SALL4 and OCT3/4 expressions in metastatic germ cell tumor (GCT). Age (years) Original tumor Diagnosis Metastatic location SALL4 OCT3/4 Follow-up period 1 50 Unknown Stage III GCT Peritoneum 3+ 0 NA 2 56 Seminoma Stage III GCT Cervical lymph node 3+ 0 4 years 3 61 Mixed GCT Stage III MGCT Cervical lymph node 3+ 3+ 4 years 4 26 Seminoma Stage III GCT Peritoneum 3+ 0 3 years 5 56 Mixed GCT with dominant seminoma Stage III GCT Gallbladder 3+ 0 NA 6 42 Unknown Stage III seminoma Peritoneum 3+ 3+ 3 years 7 49 Testicular GCT NOS Stage III yolk sac tumor Inguinal lymph node 3+ 0 2 years 8 63 Unknown Stage III GCT Adrenal 3+ 0 9 months 9 <jats:td colspan=

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e17006
Primary Topic
Renal and related cancers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Different roles of SALL4 and OCT3/4 in the development and evolving processes of benign and malignant germ cells.

Kevin Juan Zhang, Jason Hafron, Ping Zhang
Journal of Clinical Oncology
Renal and related cancers
article

Different roles of SALL4 and OCT3/4 in the development and evolving processes of benign and malignant germ cells.

Kevin Juan Zhang, Jason Hafron, Ping Zhang
article en

Abstract

e17006 Background: In gonadogenesis, OCT3/4 and SALL4 are expressed in early germ cells and are critical for maintaining their pluripotency by suppressing differentiation. It is important to understand the variable expression of these two biomarkers throughout different stages of embryonic development as well as in tumor development. The primary aim of this study was to analyze SALL4 and OCT3/4 nuclear expression in various stages of fetal testes and examine their potential link to the risk of cryptorchidism in relation to later testicular tumor development. The second aim was to investigate the different expression patterns of SALL4 and OCT3/4 in metastatic germ cell tumors (GCT). Methods: Surgical and autopsy fetal testes ranging from 10 weeks of gestation to 11 months (n=10) were immunochemically stained for SALL4 and OCT3/4. OCT3/4 and SALL4 immunostains were further tested in 12 specimens from 11 patients with metastatic GCT. Results: SALL4 expression was maintained from early gonadogenesis within germ cells and persists regardless of age or malignant transformation. Whereas OCT3/4 expression started to diminish midway through the 3 rd trimester. Expression of OCT3/4 was retained in a case of a cryptorchid testicle, suggesting that continued expression of OCT3/4 may be linked to an increased risk of GCT in individuals with cryptorchid testicles. OCT3/4 expression returned in germ cell neoplasia in situ and undifferentiated GCTs such as seminoma and embryonal carcinoma. Only 2/12 (17%) metastatic GCT were positive for both SALL4 and OCT3/4, but the majority of metastatic GCT (83% 10/12 cases) continued to evolve by losing expressions of OCT3/4 and maintaining expression of SALL4 (Table 1). Conclusions: Our data demonstrates bridging associations from OCT3/4 and SALL4 expressions in embryonal testis development to their presence in metastatic GCT, indicating a continuous evolving process from benign germ cells to malignant GCT. SALL4 is an important marker for identifying GCT in metastatic sites, whereas metastatic GCTs often lose OCT3/4 expression during progression. SALL4 and OCT3/4 expressions in metastatic germ cell tumor (GCT). Age (years) Original tumor Diagnosis Metastatic location SALL4 OCT3/4 Follow-up period 1 50 Unknown Stage III GCT Peritoneum 3+ 0 NA 2 56 Seminoma Stage III GCT Cervical lymph node 3+ 0 4 years 3 61 Mixed GCT Stage III MGCT Cervical lymph node 3+ 3+ 4 years 4 26 Seminoma Stage III GCT Peritoneum 3+ 0 3 years 5 56 Mixed GCT with dominant seminoma Stage III GCT Gallbladder 3+ 0 NA 6 42 Unknown Stage III seminoma Peritoneum 3+ 3+ 3 years 7 49 Testicular GCT NOS Stage III yolk sac tumor Inguinal lymph node 3+ 0 2 years 8 63 Unknown Stage III GCT Adrenal 3+ 0 9 months 9 <jats:td colspan=

Journal of Clinical OncologyVol. 44(16_suppl)
City of Hope (US)
Good health and well-being
Openalex Percentile: Top 9%
Renal and related cancers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.